TADA1: A Potential Drug Target and Biomarker for Cancer (G117143)

Target Name: TADA1

NCBI ID: G117143

TADA1

TADA1: A Potential Drug Target and Biomarker for Cancer

TADA1 (Tumor Antigen-Derived Alkaline Phosphatase 1) is a protein that is expressed in a variety of tissues, including the brain, heart, and pancreas. It is a member of the superfamily of alkaline phosphatases, which are a group of enzymes that regulate calcium homeostasis in cells. TADA1 is highly conserved across species, and its sequence is similar to that of other known alkaline phosphatases.

TADA1 is involved in a variety of physiological processes in the body, including cell signaling, DNA replication, and metabolism. It is a negative regulator of the calcification process, which is the process by which minerals such as calcium and phosphorus are precipitated from solution to form insoluble crystals in tissues. TADA1 is also involved in the regulation of cell proliferation, and has been shown to play a role in the development and progression of a variety of diseases, including cancer.

Due to its involvement in these processes, TADA1 has been identified as a potential drug target. Researchers have found that TADA1 is highly expressed in many types of cancer, and that inhibiting its activity may be an effective way to treat these diseases. In addition, TADA1 has been shown to be involved in a variety of cellular processes that are important for cancer cell survival, so targeting it may be a way to disrupt the signaling pathways that allow cancer cells to grow and multiply.

One of the challenges in targeting TADA1 is its diverse expression pattern across different tissues and species. However, researchers have been able to use techniques such as RNA interference and gene editing to modify the expression of TADA1 in certain cell types. This has allowed them to study the effects of TADA1 inhibitors on cancer cells, and has provided insights into the mechanisms by which TADA1 functions.

In addition to its potential as a drug target, TADA1 is also a potential biomarker for cancer. Its expression has been shown to be elevated in a variety of cancer types, and its levels may be used as a diagnostic indicator or as a target for cancer detection agents. This makes TADA1 a promising candidate for use as a diagnostic or therapeutic target in cancer treatment.

Overall, TADA1 is a protein that is involved in a variety of important cellular processes in the body. Its potential as a drug target and biomarker make it an attractive target for researchers to study, and its involvement in cancer development and progression makes it a promising target for therapeutic intervention. Further research is needed to fully understand the mechanisms by which TADA1 functions and to develop effective treatments for cancer.

Protein Name: Transcriptional Adaptor 1

Functions: Probably involved in transcriptional regulation

The "TADA1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TADA1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets